+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a new multivalent pneumococcal vaccine called PG4 in healthy infants. This vaccine is being compared to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC. The study aims to see how well the new vaccine helps fight germs that cause pneumonia, meningitis, and ear infections, and whether it provides additional protection against pneumococcal disease compared to the existing vaccine. The study includes three groups of infants based on age and location. Group 1 involves about 3000 infants who are 2 months old and will receive either PG4 or 20vPnC shots into the left thigh muscle at 2, 4, 6, and 12 to 15 months of age. Groups 2 and 3, with smaller numbers of infants from outside the United States aged 2 to 6 months, will receive different schedules of PG4 or 20vPnC either intramuscularly or under the skin. Each infant will be randomly assigned to one of the vaccine types and administration methods. Participants will be involved in the study for about 12 to 19 months depending on their group. During this time, infants will attend six clinic visits and one phone call, where parents or guardians will be asked about any side effects experienced. Blood samples will be collected three times to measure the immune response through proteins that fight the pneumococcal disease germs. The study also monitors local and systemic reactions, adverse events, and serious adverse events following vaccination.

Age: 42Days - 211DaysAll GendersPhase 3
130 locations
S

Actively Recruiting

Researchers are evaluating the safety, how the body processes, and how well the study medicine nirmatrelvirritonavir works for treating COVID-19 in children under 18 years old who are not hospitalized but at risk of severe illness. This trial is a Phase 3, open-label study focusing on nonhospitalized pediatric patients with COVID-19 to better understand the effects of this oral medication. The study medicine is given by mouth as tablets or powder twice daily for 5 days, totaling 10 doses. Different dosing forms and amounts are used depending on the participants age and weight, ranging from under 1 month old up to 18 years. Participants are assigned to one of several groups based on these factors to receive the medicine accordingly. During the study, participants will have blood samples taken to measure drug levels at specific times, and researchers will monitor for any side effects or changes in vital signs up to 34 days after starting treatment. They will also measure viral load through nasal swabs at several points over 28 days and assess hospitalizations or deaths related to COVID-19. Participants feedback on the medicines taste and acceptability will be collected during treatment.

Age: 0Years - 17YearsAll GendersPhase 3
73 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating three lots of an investigational 21-valent pneumococcal conjugate vaccine PCV21 to see if they produce similar immune responses and are safe compared to a licensed 20-valent pneumococcal vaccine 20vPCV in healthy infants aged approximately 2 months. This phase 3, randomized, modified double-blind study aims to measure antibody development and safety of these vaccines as part of routine pediatric immunization. Participants will receive four doses of either one of three PCV21 vaccine lots or the 20vPCV comparator at about 2, 4, 6, and 12 months of age through intramuscular injections. The study includes two cohorts Cohort A, which is randomized to three PCV21 groups or one 20vPCV group, and Cohort B, randomized to three PCV21 groups only. All vaccinations are co-administered with routine pediatric vaccines as per local recommendations. Throughout the study, participants will attend six visits spaced over approximately 17 months. Researchers will collect blood samples to measure immune response 30 days after the third vaccine dose and monitor immediate and longer-term adverse events after each injection. Safety and immunogenicity are assessed through questionnaires, medical evaluations, and lab tests, with monitoring continuing up to six months after the final vaccine dose.

Age: 42Days - 89DaysAll GendersPhase 3
25 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a new pneumococcal vaccine called PG4 compared to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC in children and adolescents. The study aims to see how well the new vaccine helps the body fight germs that cause pneumonia, meningitis, and ear infections. It includes children aged 15 months to less than 18 years, some of whom may have previously received pneumococcal vaccines. Participants will be divided into three age groups 15 months to under 2 years, 2 to under 5 years, and 5 to under 18 years. Within each group, participants will be randomly assigned in a 21 ratio to receive a single injection of either the new vaccine PG4 or the existing 20vPnC vaccine, given in the arm or thigh. The study is conducted across multiple countries including the United States and Puerto Rico. Each participant will be involved for about 6 months, attending two clinic visitsone for vaccination and one for follow-upand one telephone follow-up. Blood samples will be collected at visits to measure immune response, and participants will be monitored for local and systemic reactions, adverse events, and serious adverse events throughout the study period. The study evaluates immune system protein levels and antibody activity one month after vaccination to compare the vaccines effects.

Age: 15Months - 17YearsAll GendersPhase 3
77 locations